A detailed history of Td Asset Management Inc transactions in Rhythm Pharmaceuticals, Inc. stock. As of the latest transaction made, Td Asset Management Inc holds 31,800 shares of RYTM stock, worth $1.77 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
31,800
Previous 31,000 2.58%
Holding current value
$1.77 Million
Previous $1.27 Million 30.97%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 01, 2024

BUY
$40.81 - $55.0 $32,648 - $44,000
800 Added 2.58%
31,800 $1.67 Million
Q2 2024

Aug 02, 2024

BUY
$35.41 - $44.37 $120,393 - $150,858
3,400 Added 12.32%
31,000 $1.27 Million
Q1 2024

May 08, 2024

SELL
$39.12 - $52.44 $399,024 - $534,888
-10,200 Reduced 26.98%
27,600 $1.2 Million
Q4 2023

Feb 12, 2024

BUY
$21.39 - $49.64 $808,542 - $1.88 Million
37,800 New
37,800 $1.74 Million
Q1 2020

May 15, 2020

SELL
$13.16 - $22.9 $282,400 - $491,411
-21,459 Closed
0 $0
Q3 2019

Nov 07, 2019

SELL
$18.62 - $24.51 $20,482 - $26,961
-1,100 Reduced 4.88%
21,459 $463,000
Q2 2019

Aug 01, 2019

BUY
$21.11 - $28.48 $82,329 - $111,072
3,900 Added 20.9%
22,559 $496,000
Q1 2019

May 08, 2019

BUY
$24.76 - $31.66 $81,708 - $104,478
3,300 Added 21.49%
18,659 $511,000
Q4 2018

Feb 01, 2019

BUY
$24.11 - $31.34 $19,215 - $24,977
797 Added 5.47%
15,359 $413,000
Q3 2018

Nov 01, 2018

BUY
$26.99 - $35.85 $78,351 - $104,072
2,903 Added 24.9%
14,562 $425,000
Q2 2018

Jul 31, 2018

BUY
$17.02 - $35.2 $198,436 - $410,396
11,659 New
11,659 $364,000

Others Institutions Holding RYTM

About RHYTHM PHARMACEUTICALS, INC.


  • Ticker RYTM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,720,000
  • Market Cap $3.11B
  • Description
  • Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convert...
More about RYTM
Track This Portfolio

Track Td Asset Management Inc Portfolio

Follow Td Asset Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Td Asset Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Td Asset Management Inc with notifications on news.